Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAFAIR versus NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE.
GENTAFAIR vs NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and cell death. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
1-2 drops of ophthalmic solution (neomycin 3.5 mg/mL and dexamethasone 1 mg/mL) or ointment (neomycin 3.5 mg/g and dexamethasone 1 mg/g) into the affected eye(s) every 4-6 hours; in severe cases, every 1-2 hours initially and tapered. For otic use: 3-4 drops into the affected ear(s) 3-4 times daily. Topical: apply thin layer to affected area 1-3 times daily.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Neomycin: 2-3 h (topical/ophthalmic absorption minimal; if significant, prolonged in renal impairment). Dexamethasone: 4-6 h (ophthalmic, systemic if absorbed).
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Renal: neomycin ~30-80% unchanged; dexamethasone phosphate ~80% as free/free glucuronide metabolites. Fecal: negligible.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic